Lucid Diagnostics Inc. LUCD
0.39 USD -0.01 (-3.14%)
As ofNov 17, 2026, 9:37 AM EST
0.3851 Day range 0.40
0.303 52-week range 1.63
- YTD
- -64.65%
- 1 year
- -63.99%
News
prnewswire.com PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results Lucid Diagnostics' EsoGuard ® now fully reimbursed by Medicare nationwide Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
marketbeat.com What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call Lucid Diagnostics NASDAQ: LUCD said Medicare payments for its EsoGuard esophageal pre-cancer test have begun through its Texas laboratory, prompting the company to redirect its sales efforts toward…
seekingalpha.com Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript
zacks.com Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.benzinga.com Lucid Diagnostics Q3 Adj. EPS $(0.06), Inline, Sales $1.203M Miss $1.635M Estimate Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.10) per share from the same…
prnewswire.com Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results EsoGuard ® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter Conference call and webcast…benzinga.com PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes The manuscript, "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," published in the journal Diagnostics, reported that…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
benzinga.com Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…benzinga.com Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21 On September 22, Lucid announced that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
